Showing results (881-890 of 1,190) with videos related to
Sort By:
Pageof 119
Cancer|January 31, 2020
Long-term results of frontline dasatinib in chronic myeloid leukemiaAbhishek Maiti, Jorge E Cortes, Keyur P Patel, et al.American Journal of Hematology|January 12, 2017
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agentsElias Jabbour, Paolo Strati, Monica Cabrero, et al.Cancers|November 27, 2024
Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients: The MD Anderson Cancer Center ExperienceDavid McCall, Shaikha Alqahtani, Moriah Budak, et al.Blood Advances|March 21, 2024
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasmAlex Bataller, Georgina Gener-Ricos, Emmanuel Almanza-Huante, et al.Cytotherapy|February 1, 2014
Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host diseaseSimrit Parmar, Xiaoying Liu, Shawndeep S Tung, et al.Leukemia Research|February 12, 2025
Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletionKensuke Takaoka, Rami Komrokji, Kelly Chien, et al.Journal of Hematology & Oncology|May 2, 2023
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemiaHagop Kantarjian, Fadi G Haddad, Nitin Jain, et al.Biorxiv : the Preprint Server for Biology|April 17, 2023
Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS -mutated chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Feiyang Ma, Natthakan Thongon, et al.Cancer|November 21, 2014
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research ConsortiumElias J Jabbour, Guillermo Garcia-Manero, Paolo Strati, et al.American Journal of Hematology|July 29, 2023
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failureSamuel Urrutia, Kelly S Chien, Ziyi Li, et al.Pageof 119